Testing solutionsSpanning the Lung Cancer Continuum of Care Access fast, reliable, and actionable biological insights with our genomic and proteomic tests to gain a deeper understanding of each patient’s disease state, help expedite diagnosis, and guide confident treatment decisions. ...
Testing solutionsSpanning the Lung Cancer Continuum of Care Access fast, reliable, and actionable biological insights with our genomic and proteomic tests to gain a deeper understanding of each patient’s disease state, help expedite diagnosis, and guide confident treatment decisions. ...
The Quest Advanced Oncology LungSEQ Concurrent Panel, part of our comprehensive solution for lung cancer diagnostics, is a disease-targeted NGS panel. We’ve developed these and other decision-support tools to help physicians create a treatment plan for navigating within standard of care and clinical...
In particular, performing CT scan before bronchoscopy, PET scan before surgery and avoiding tests that give only diagnosis when information on staging is also needed to guide treatment. We report current UK practice for lung cancer patients diagnosed following a GP referral and assess the impact of...
Diagnostic compositions include compositions comprising detection agents for detecting one or more genes that have been shown to be up-or down-regulated in pathogenesis of lung cancer. Exemplary detection agents include nucleic acid probes, which can be in solution or attached to a solid surface, e...
Introduction: Lung cancer is the second mortality cause in Mexico, therefore, the main objective of this study was to determine the degree of diagnostic certainty of histology and cytology studies used at the National Institute of Respiratory Disease, where a sample quality control method is also ...
“The survival rate of stage 1A lung cancer at 10 years is over 90%. Yet for late-stage lung cancer patients, the survival drops significantly and only the 5-year survival rate is calculated,” says Frank Shi, CEO of Sanmed Biotech. “Early diagnosis of lung cancer is critical in reduci...
The lung cancer diagnostics market was valued at US$ 15.1 Bn in 2023, It is projected to grow at a CAGR of 7.9% from 2024 to 2034 and reach more than US$ 34.8 Bn by the end of 2034
Diagnostics markers for lung cancer 专利名称：Diagnostics markers for lung cancer 发明人：PAULA K. RICKERT,RANDI KRASNOW 申请号：AU2003240495 申请日：20030602 公开号：AU2003240495A8 公开日：20031219 专利内容由知识产权出版社提供 摘要：The present invention relates to a combination comprising a plurality ...
Objectives: To assess immunohistochemical (IHC) stains differentially expressed between different types of lung cancer.Methods: We evaluated 16 different IHC stains in 209 prospectively included, surgically treated primary lung cancers, including 121 adenocarcinomas, 65 squamous cell carcinomas, 15 large-ce...